HHS Analysis Shows Higher Drug Prices Outpacing Inflation
October 6, 2022
According to a new U.S. Department of Health and Human Services (HHS) analysis, in 2022, the list prices of over
Menu
Make Prescription Drugs More Affordable
Medicare Rights Urges Swift Passage of the Inflation Reduction Act of 2022
August 6, 2022
—Statement from Fred Riccardi, Medicare Rights Center President— Washington DC—The Medicare Rights Center strongly supports the Inflation Reduction Act of
As Congress Looks to Address Medicare Prescription Drug Affordability, Now Is the Time to Make Your Voice Heard
August 4, 2022
As recently outlined, the Inflation Reduction Act of 2022 incorporates many of Medicare Rights’ long-standing recommendations to meaningfully improve the
Senate Democrats Release Updated Prescription Drug Pricing Bill
July 14, 2022
Last week, Senate Democrats released updated prescription drug pricing legislation, with the goal of passing it through the reconciliation process
Medicare Rights Trends Report Shows Part D Enrollees Continue to Struggle with Costs and Other Barriers to Care
June 9, 2022
This is part 3 of the helpline trends report series. Read part 1, part 2, and part 4. This third
New Campaign Urges Senate Action on Prescription Drug Pricing
May 12, 2022
Medicare Rights recently joined over 70 organizations to launch the campaign “Push For Lower Rx Prices.” The groups are calling
Drug Prices Remain High and Unpredictable as Beneficiaries Look to Lawmakers for a Fix
May 5, 2022
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
Further Evaluation of Potential Caps in Part D Shows Promise for Beneficiary Impact
April 14, 2022
A recently released report from the Urban Institute shows that a firm limit on out-of-pocket (OOP) Part D costs, like
New KFF Report Examines Beneficiary Exposure to Part B Drug Costs
March 17, 2022
A new brief from the Kaiser Family Foundation (KFF) examines the often extreme cost liability that Part B covered drugs—typically,
Drug Prices Already Rising in 2022
March 10, 2022
A new analysis from the AARP Public Policy Institute finds drug companies have increased prices for many brand name Part
HHS Analysis Shows Higher Drug Prices Outpacing Inflation
October 6, 2022
According to a new U.S. Department of Health and Human Services (HHS) analysis, in 2022, the list prices of over
Medicare Rights Urges Swift Passage of the Inflation Reduction Act of 2022
August 6, 2022
—Statement from Fred Riccardi, Medicare Rights Center President— Washington DC—The Medicare Rights Center strongly supports the Inflation Reduction Act of
As Congress Looks to Address Medicare Prescription Drug Affordability, Now Is the Time to Make Your Voice Heard
August 4, 2022
As recently outlined, the Inflation Reduction Act of 2022 incorporates many of Medicare Rights’ long-standing recommendations to meaningfully improve the
Senate Democrats Release Updated Prescription Drug Pricing Bill
July 14, 2022
Last week, Senate Democrats released updated prescription drug pricing legislation, with the goal of passing it through the reconciliation process
Medicare Rights Trends Report Shows Part D Enrollees Continue to Struggle with Costs and Other Barriers to Care
June 9, 2022
This is part 3 of the helpline trends report series. Read part 1, part 2, and part 4. This third
New Campaign Urges Senate Action on Prescription Drug Pricing
May 12, 2022
Medicare Rights recently joined over 70 organizations to launch the campaign “Push For Lower Rx Prices.” The groups are calling
Drug Prices Remain High and Unpredictable as Beneficiaries Look to Lawmakers for a Fix
May 5, 2022
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
Further Evaluation of Potential Caps in Part D Shows Promise for Beneficiary Impact
April 14, 2022
A recently released report from the Urban Institute shows that a firm limit on out-of-pocket (OOP) Part D costs, like
New KFF Report Examines Beneficiary Exposure to Part B Drug Costs
March 17, 2022
A new brief from the Kaiser Family Foundation (KFF) examines the often extreme cost liability that Part B covered drugs—typically,
Drug Prices Already Rising in 2022
March 10, 2022
A new analysis from the AARP Public Policy Institute finds drug companies have increased prices for many brand name Part